L & S Advisors’s CRISPR Therapeutics CRSP Stock Holding History

L & S Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-7,500	Closed	-$568K	–	286
2021 Q4	$568K	Sell	7,500 -8,006	-52%	-$699K	0.06%	212
2021 Q3	$1.74M	Buy	15,506 +5,948	+62%	+$747K	0.19%	154
2021 Q2	$1.55M	Sell	9,558 -4,032	-30%	-$490K	0.17%	179
2021 Q1	$1.66M	Sell	13,590 -39	-0.3%	-$5.89K	0.19%	174
2020 Q4	$2.09M	Buy	13,629 +3,377	+33%	+$399K	0.24%	145
2020 Q3	$857K	Sell	10,252 -373	-4%	-$33.1K	0.12%	195
2020 Q2	$781K	Buy	+10,625	New	+$621K	0.12%	188
2018 Q4	–	Sell	-11,070	Closed	-$491K	–	306
2018 Q3	$491K	Sell	11,070 -7,215	-39%	-$378K	0.06%	221
2018 Q2	$1.07M	Buy	+18,285	New	+$1.04M	0.18%	130

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

L & S Advisors's CRSP Position: Q1 2022 in Review

L & S Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 7,500 shares — an estimated $568K sold.

L & S Advisors first reported a position in CRSP in Q2 2018 and held it in 9 quarters. The position peaked at $2.09M in Q4 2020. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

L & S Advisors reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
L & S Advisors sold 7,500 CRISPR Therapeutics shares in Q1 2022, an estimated $568K.
L & S Advisors first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 9 quarters.
L & S Advisors's CRISPR Therapeutics position peaked at $2.09M in Q4 2020.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on L & S Advisors's 13F filing for Q1 2022, filed 11 May 2022.